Transparent, flexible pharmaceutical lead generation pricing.
Monthly retainer model — custom to your therapeutic area, value-chain position, target buyers, and evaluation cycle. Everything you need for predictable pharma and life-sciences pipeline growth, no template package.
Four factors determine your scope.
Every pharma and life-sciences engagement is scoped to your operation. The four factors below shape both the team we assemble and the price.
Therapeutic area and modality complexity
Small molecule vs. biologic vs. cell and gene therapy, regulated buyer profiles (PharmD, principal scientist, QA and regulatory director), and the depth of scientific framing each requires. More technical modalities and senior, credential-gated buyers cost more to engage.
Value-chain position you sell from
Whether you sell as a manufacturer, CDMO, CRO, distributor, or service provider — each motion targets a different buyer and message. A contract manufacturer selling capacity, a distributor selling reach, and a manufacturer selling a therapeutic story all require their own playbook and orchestration.
Regulated-buyer access and compliance overhead
Vendor qualification, GxP expectations, NDAs, and audit-trail requirements mean you can’t cold-blast a list. Documented, consent-aware outreach that respects how regulated buyers are allowed to engage adds upfront effort — but it’s what keeps first contact building trust instead of triggering a compliance flag.
Target volume and evaluation cycle length
Monthly target volume, ramp speed, and how long buyers take to move. Pharma evaluations commonly run 9 to 18 months — high-volume targets and longer, multi-stakeholder cycles require more dial hours, more nurture, and more SDR coverage to keep the relationship alive to the close.
Every pharma engagement includes:
No à la carte add-ons. The full engine is in scope from week one.
- Dedicated life-sciences-trained SDR team with custom scripts in your brand voice
- Transparent reporting — activity, qualification context, and pipeline visibility
- Regular partnership meetings reviewing KPIs and adjusting messaging weekly during ramp
- Multi-channel execution prioritized to your therapeutic areas, modalities, and value-chain segments
- High-fidelity buyer data aligned to your ICP — therapeutic area, value-chain position, GxP and accreditation status
One definition of qualified. All three.
Every appointment we put on your AE’s calendar meets a three-point standard before it lands.
- Verified pain — the buyer has named a specific capacity, supplier, therapeutic, or compliance problem
- Decision authority — they can sign for the contract, or they’re one of two people who can
- Active timeline — they’re evaluating in the next 90 days, not exploring options indefinitely
Anything short of all three doesn’t make your AE’s calendar. Most agencies count anything with a pulse as a “lead.” We don’t.
Four questions about how we scope and bill.
Do you publish prices?
No. Every pharmaceutical lead generation program is custom to your therapeutic focus, value-chain position, target buyers, and KPIs. We don’t publish a rate card because a flat price would either overcharge half our clients or undercharge the other half. Book the assessment and you’ll get a written scope and quote within 30 minutes.
How soon can we start?
Immediately after agreement execution. Onboarding runs 5-10 business days, and outreach starts in week one.
Is there a cancellation policy?
Yes — cancellation terms are outlined in your agreement.
How do you ensure ROI?
We set shared KPIs upfront, provide transparent reporting, and optimize messaging continuously based on real call data. ROI for outbound is dictated by what the close side does with the appointments we deliver — we own everything up to the calendar.
30-minute call. Written scope and quote.
We’ll review your therapeutic focus, value-chain position, and target buyers — then walk you out with a written scope and quote before the call ends. No deck. No template.